Eli Lilly's new oral weight loss pill, orforglipron, shows promise in Phase 3 trials, offering a convenient alternative to ...

A new weight-loss pill taken daily could compete with injections like Ozempic, new research suggests. Patients, who all were ...

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its ...

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly says its GLP-1 drug in pill form is as safe and effective as Ozempic and other mega-popular injectable drugs for weight loss and lowering blood sugar. The company announ ...

Once-daily orforglipron was more effective than placebo and just as safe as injectable GLP-1s in patients with diabetes and ...